Cell therapy weekly: International Stem Cell Corporation announces successful Phase I trial for ISC-hpNSC^® in the treatment of Parkinson’s disease

This week: the International Stem Cell Corporation has announced successful completion of its Phase I trial for ISC-hpNSC® in the treatment of Parkinson’s disease, RepliCel applies for manufacturing approval of its collagen and tissue regeneration cell therapies, and Bone Therapeutics secures up to €16 million from the European Investment Bank to accelerate its ongoing clinical and commercial development of orthopedic treatments. The news highlights: International Stem Cell Corporation announces successful Phase I trial for ISC-hpNSC® in the treatment of Parkinson’s disease RepliCel applies for manufacturing approval for its collagen and tissue regeneration cell therapies Bone Therapeutics secures up to €16 million...